Treatment of histoplasmosis with MK-991 (L-743,872)

John R. Graybill, Laura K. Najvar, Eleanor M. Montalbo, Francesco J. Barchiesi, Michael F. Luther, Michael G. Rinaldi

Research output: Contribution to journalArticlepeer-review

71 Scopus citations


BALB/c nu/+ immunocompetent and athymic (nu/nu) mice were infected intravenously with yeast cells of Histoplasma capsulatum. Mice were either given water (controls) intraperitoneally (i.p.) or given MK-991 i.p. once daily or twice daily. Protection was measured as prolonged survival or reduction in tissue counts. MK-991 was protective in immunocompetent mice, prolonging survival and reducing counts in spleen and livers at a dose as low as 0.05 mg/kg of body weight/day. MK-991 was modestly effective in athymic mice at a higher dose, 5 mg/kg/day. These studies suggest that MK-991 may be appropriate for clinical development in histoplasmosis.

Original languageEnglish (US)
Pages (from-to)151-153
Number of pages3
JournalAntimicrobial agents and chemotherapy
Issue number1
StatePublished - Jan 1998
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Treatment of histoplasmosis with MK-991 (L-743,872)'. Together they form a unique fingerprint.

Cite this